FDA Risk Panel DXM Meeting Raises Stakes on Age Restriction Movement
This article was originally published in The Tan Sheet
Executive Summary
A Drug Safety and Risk Management Advisory Committee meeting scheduled for Sept. 14 on the potential for abuse of the cough suppressant dextromethorphan could bring the OTC industry's next regulatory nightmare
You may also be interested in...
Consumer OTC Ingredient Survey Reveals Need For Education
A CHPA-funded survey found one-third of consumers do not understand what common OTC ingredients do – putting them at risk for using the wrong drug or overdosing. The trade group and firms can educate these consumers through a stronger online presence, by working with providers and giving necessary information to key influencers.
Consumer OTC Ingredient Survey Reveals Need For Education
A CHPA-funded survey found one-third of consumers do not understand what common OTC ingredients do – putting them at risk for using the wrong drug or overdosing. The trade group and firms can educate these consumers through a stronger online presence, by working with providers and giving necessary information to key influencers.
FDA Panel Says Leave DXM Unscheduled For Now, Urges Congressional Action
Dextromethorphan likely will escape scheduling as a controlled substance in the near term, but manufacturers and lawmakers should push efforts to curb abuse to keep the cough suppressant available OTC in the long run